Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001725160-24-000168
Filing Date
2024-10-31
Accepted
2024-10-31 20:59:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 2873
  Complete submission text file 0001725160-24-000168.txt   4613
Mailing Address C/O ONCOTHYREON INC. 2601 FOURTH AVE, SUITE 500 SEATTLE WA 98121
Business Address
HAUSMAN DIANA (Reporting) CIK: 0001563992 (see all company filings)

Type: 144

Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Subject) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39263 | Film No.: 241416728
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)